[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cigarette-smoking\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cigarette-smoking":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,42,79,106,128,152,175,198,222,245,267,298,318,339,369,388,416,436,459,483,504,515,544,565],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054115","switch-or-quit-r01-100054115",false,"NCT06373679","Switch or Quit R01","Non-cigarette Tobacco Products as Harm Reduction Tools in Smokers Who Failed to Quit With Traditional Methods","Inclusion Criteria\n\n* Adults 21+ who previously had a quit attempt using FDA-approved pharmacotherapy.\n* Interest in reducing harms from tobacco use or quitting smoking\n\nExclusion Criteria\n\n* Pregnant, breastfeeding, or trying to become pregnant.\n* Household member currently enrolled in the study\n* Planning to move out of the area within the next 7 months",true,"ALL","21 Years",{"count":20,"type":21},225,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates whether non-cigarette tobacco products (e-cigarettes) can help smokers quit smoking as compared to traditional quit methods (nicotine replacement therapy or varenicline\u002FChantix). Participants in this study will be randomly assigned to one of two groups, then will have a choice between the offered products of that group. Participants in the e-cigarette group will have a choice of e-cigarette brand and flavor. Participants in the medication group will have choice between nicotine replacement therapy (patches and lozenges) or varenicline, also known as Chantix. Participation will last 6 months and will include weekly phone calls for the initial 7-weeks plus a 11-week phone call and a 6-month follow-up visit. Participants will also complete electronic daily diaries during the first 7-weeks.",[27,28],"Cigarette Smoking","Smoking Behaviors","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2024-07-10",{"date":37,"type":21},"2027-05-01",{"name":39,"class":40},"Medical University of South Carolina","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100590357","phase-4-varenicline-for-smoking-reduction-in-veterans-not-ready-to-quit-100590357","NCT06966362","Varenicline for Smoking Reduction in Veterans Not Ready To Quit","Varenicline for Smoking Reduction in Veterans Unwilling to Quit","Inclusion Criteria:\n\n* Report smoking an average of 5 or more cigarettes daily for the previous 6 months\n* Not ready to set a quit date in the next 30 days but willing to cut down on their smoking\n* Able to read, write, and speak English\n* Be medically eligible to use study medications (NRT or varenicline)\n* If female, use an approved method of birth control while using study medication\n* Be at least 21 years old\n* Be a Veteran\n\nExclusion Criteria:\n\n* Unable to give informed, voluntary consent to participate\n* Current use of any pharmacotherapy for smoking cessation\n* Use of non-cigarette tobacco products as primary form of tobacco use\n* Incarceration",{"count":50,"type":21},400,[52],"PHASE4","In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.",[55,56,27,57],"Veterans","Tobacco Use Disorder","Tobacco Dependence",[59,60,55,61,62,63,64,65,66],"Varenicline","Tobacco use disorder","Quit attempts","Cigarette smoking","Motivation phase treatment","Nicotine replacement therapy","Smoking reduction","Smoking abstinence","NOT_YET_RECRUITING","2026-06-18",{"date":70,"type":33},"2026-06-22",{"date":72,"type":21},"2026-07-20",{"date":74,"type":21},"2030-06-28",{"name":76,"class":77},"VA Office of Research and Development","FED",4,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100608281","catalyzing-cigarette-smoking-cessation-through-harm-reduction-sampling-among-people-unmotivated-to-quit-100608281","NCT07199517","Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e., speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. Have a carbon monoxide (CO) greater than or equal to 10 ppm\n4. Not using any forms of nicotine regularly other than cigarettes.\n5. Not interested in quitting smoking in the next 30 days.\n6. Capable of giving written informed consent, including compliance with the requirements and restrictions listed in the combined consent and HIPAA form\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, IQOS, ONPS, etc.).\n2. Current or impending (during the study period) enrollment or plans to enroll in a smoking cessation program.\n3. Current use of smoking cessation medication.\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, uncontrolled hypertension, cardiovascular event).\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",{"count":86,"type":21},472,[24],"This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choose one of two harm-reduction products (ECIG, ONP) versus a medicinal nicotine control condition (nicotine patch + lozenge, NPL), receive a 4-week starter product regimen, and then be followed for 6 months to assess use behavior.",[27,90,91],"Tobacco Use","Cigarette Smoking Behavior",[93,94,95,96],"cigarette smoking","harm reduction","sampling","nicotine replacement","2026-06-10",{"date":99,"type":33},"2026-06-11",{"date":101,"type":33},"2026-01-12",{"date":103,"type":21},"2030-07-31",{"name":105,"class":40},"Abramson Cancer Center at Penn Medicine",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100620336","remote-interventions-for-menthol-cigarette-use-100620336","NCT07356297","Remote Interventions for Menthol Cigarette Use","Comparing Remotely-delivered Interventions to Promote Cessation Among Adults Who Smoke Menthol Cigarettes","Inclusion Criteria:\n\n* adults (ages 18+) who call partnered quitlines (QL); and\n* currently smoke menthol cigarettes; and\n* are fluent in English; and\n* plan to live in the United States for the full trial duration; and\n* have daily smartphone access (including data access) or are willing to use a study-provided smartphone and data plan\n* ability to provide informed consent\n\nExclusion Criteria:\n\n* not ready to set a quit date within 30 days; or\n* have not smoked in the past 7 days\n* Inability to speak\u002Funderstand English\n* Conditions precluding informed consent or understanding of intervention or assessment content\n* PI discretion","18 Years",{"count":115,"type":21},1200,[24],"The purpose of this study is to evaluate whether a digital, incentive-based program, used in conjunction with traditional quitline (QL) services, can be beneficial to quitline callers who smoke menthol cigarettes. The services evaluated focus on coaching, support, and\u002For incentives for individuals who wish to quit smoking.",[27],"2026-05-20",{"date":121,"type":33},"2026-05-26",{"date":123,"type":21},"2026-09",{"date":125,"type":21},"2030-04",{"name":127,"class":40},"University of Michigan",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100603911","effects-of-tax-proposals-and-cigarette-availability-on-tobacco-purchasing-100603911","NCT07142668","Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing","The Impact of Availability of Conventional Cigarettes and LNCs in the Context of Innovative Tax Proposals","Inclusion Criteria:\n\n* provide informed consent\n* provide a breath carbon monoxide sample ≥ 8 ppm,\n* be at least 21 years of age (the legal age to purchase tobacco),\n* smoke at least 10 cigarettes daily, and\n* use other tobacco products less than weekly.\n\nExclusion Criteria:\n\n* report uncontrolled physical or mental health conditions (e.g., uncontrolled diabetes, high blood pressure, major depressive disorder, etc.),\n* use of smoking cessation medications (e.g., nicotine replacement, bupropion, varenicline) in the past 30 days,\n* report concrete, immediate plans to alter\u002Fquit using their usual tobacco products in the next 30 days,\n* be pregnant or lactating, or\n* have plans to move out of the area during the experiment.",{"count":136,"type":21},316,[24],"This study will investigate the effects of normal-nicotine versus low-nicotine cigarette availability in the context of four tax proposals (Tobacco Parity, Nicotine-Content, Harm-Reduction, and Modified Risk Tobacco Product-based taxes) on tobacco product purchasing patterns in a virtual marketplace.",[27],[141],"Experimental Tobacco Marketplace","2026-05-15",{"date":144,"type":33},"2026-05-19",{"date":146,"type":33},"2025-08-14",{"date":148,"type":21},"2026-09-30",{"name":150,"class":40},"Virginia Polytechnic Institute and State University",2,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":41},"100484386","phase-4-beta-adrenergic-modulation-of-drug-cue-reactivity-100484386","NCT05587361","Beta-Adrenergic Modulation of Drug Cue Reactivity","Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms","Inclusion Criteria:\n\n1. Generally healthy\n2. Age 21-60\n3. Right-handed using a three-item scale\n4. Daily smoker of ≥ 5 cigarettes\u002Fday delivering 0.5 mg nicotine (FTC)\n5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months\n6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and\u002For morning urinary cotinine \\>100 ng\u002Fml\n7. Must identity at least 4 different smoking locations used in a typical week\n8. Able to read and understand English\n\nExclusion Criteria:\n\n1. Inability to attend all required sessions\n2. Significant health problems that would preclude active participation\n3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)\n4. Current use of psychoactive medications\u002Fdrugs as indicated by self-report or urine screen\n5. Positive breath alcohol concentration\n6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females)\n7. Problems with vision that cannot be corrected with contacts or glasses\n8. Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes)\n9. Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications\n10. Systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg (sitting or standing)\n11. Abnormal EKG\n12. Presence of severe anemia\n13. Presence of electrolyte imbalance that could impact blood pressure\n14. Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)","60 Years",{"count":161,"type":21},80,[52],"This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.",[56,165,27],"Nicotine Dependence","2026-04-27",{"date":168,"type":33},"2026-04-28",{"date":170,"type":33},"2024-11-26",{"date":172,"type":21},"2027-03-31",{"name":174,"class":40},"University of Oklahoma",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":16,"sex":17,"minAge":113,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":41},"100546475","development-of-a-mobile-health-intervention-for-electronic-cigarette-use-among-young-adults-100546475","NCT06395415","Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults","EQUIP","Inclusion Criteria:\n\n1. Age 18-26 years old, ability to understand the English language, willing and able to provide informed consent\n2. Current ENDS user (at least 4 out of 7 days per week of use for the past one month); for focus groups, at least half of participants will report current cigarette smoking (at least 1 cigarette per day on at least 1 day per week in the past month)\n3. Report interest in quitting or reducing ENDS (at least 6\u002F10 scale in interest of quitting or reducing\n4. Does not currently (in past one year) meet criteria for major psychiatric disorder including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder\n5. For women, not currently pregnant, planning to become pregnant, or breastfeeding due to lack of information on ENDS use and possible harms from NRT during pregnancy\n6. Not currently using smoking cessation medication (i.e., Varenicline, Bupropion\n7. No history of adverse reactions to nicotine replacement therapy\n\nExclusion Criteria:\n\n1. Does not own a mobile phone or is unwilling to receive text messages to their device\n2. No interest in quitting or reducing use of ENDS\n3. Uses electronic cigarettes less than 4 days per week in the past month\n4. Reports past-year serious psychiatric illness, including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder\n5. Is currently using smoking cessation medication including Varenicline or Bupropion\n6. Are a female who is currently pregnant or nursing or planning to become pregnant within the next 6 months","26 Years",{"count":184,"type":21},46,[24],"Electronic Nicotine Delivery Systems (ENDS) use remains prevalent among young adults, and many have high interest in quitting, yet research on effective intervention is lacking. A mobile health (mHealth) intervention that translates effective smoking cessation materials and pharmacotherapy may be a promising avenue for intervention. The initial phase of the proposed study uses a pilot study to evaluate a novel mHealth intervention for young adult ENDS and dual product (ENDS and combustible cigarette) users.",[188,189,27],"Electronic Nicotine Delivery Systems","Tobacco Products","2026-04-24",{"date":166,"type":33},{"date":193,"type":33},"2025-04-25",{"date":195,"type":21},"2026-08",{"name":197,"class":40},"University of Chicago",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":41},"100533947","menthol-inflammation-and-nicotine-transition-study-100533947","NCT06232447","Menthol, Inflammation, and Nicotine Transition Study","Effect of Menthol to Non-Menthol Cigarette Switching on Subclinical Inflammatory Biomarkers of Cardiovascular Health: Simulating a Menthol Cigarette Ban","MINT","Inclusion criteria\n\n* Men and women between 21-85 years old\n* Currently uses menthol cigarettes\n* Daily smoking rate of ≥5 cigarettes\u002Fday for ≥1 year\n* Currently own and regularly use an iOS\u002FAndroid smartphone device able to download the LifeData application\n* Able to read and communicate fluently in English\n\nExclusion criteria\n\n* Currently pregnant or breastfeeding\n* Actively trying to quit smoking\n* Current heavy alcohol use\n* Frequent use of non-menthol cigarettes, other smoking products, or illicit substances\n* History of severe medical\u002Fpsychiatric condition or treatment","85 Years",{"count":208,"type":21},68,[24],"This study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.",[27,212],"Inflammatory Response","2026-04-14",{"date":215,"type":33},"2026-04-16",{"date":217,"type":33},"2024-03-26",{"date":219,"type":21},"2027-06",{"name":221,"class":40},"Rosalind Franklin University of Medicine and Science",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":16,"sex":17,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":151},"100431816","rtms-targets-neural-circuits-for-smoking-cessation-100431816","NCT04903028","RTMS Targets Neural Circuits for Smoking Cessation","RTMS Manipulates Imbalanced Drive-reward and Executive Control Circuitry for Smoking Cessation","Inclusion Criteria\n\n* Be between the ages of 22 and 70 years old.\n* Smoke 10 or more cigarettes per day and have a carbon monoxide (CO) level \\> 10 ppm indicative of recent smoking.\n* Have not received substance abuse treatment within the previous 30 days.\n* Meet the criteria for tobacco use disorder as determined by DSM-5.\n* Be in stable mental and physical health.\n* If female, test non-pregnant and use adequate birth control.\n* Show no evidence of focal or diffuse brain lesions on MRI.\n* Be willing to provide informed consent.\n* Be able to comply with protocol requirements and likely to complete all study procedures.\n* Be motivated to quit smoking (based on responses of \"very likely,\" or \"somewhat likely\" in the motivation questionnaire).\n\nExclusion Criteria\n\n* Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria.\n* Contraindications to MRI (e.g., presence of metal in the skull, orbital or intracranial cavity, or having claustrophobia).\n* Contraindication to rTMS.\n* History of autoimmune, endocrine, viral, or vascular disorders affecting the brain.\n* History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.\n* Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea.\n* Lifetime history of major Axis I disorders such as: bipolar affective disorder (BPAD), schizophrenia, post-traumatic stress disorder (PTSD), dementia, suicidal ideation or major depression.\n* Self-report of \\>21 standard alcohol drinks per week in any week in the 30 days prior to screening.\n* Use of other forms of nicotine delivery, such as nicotine patches, electronic cigarettes, gum, nasal spray, inhalers, and nicotine lozenges.\n* Use of other tobacco products, including cigars, cigarillos, chew, snuff, and pouches\u002Fsnus.\n* Previous treatment with TMS.","22 Years","70 Years",{"count":232,"type":21},64,[24],"Cigarette smoking is a significant public health concern. Transcranial magnetic stimulation (TMS) is a non-invasive form of brain stimulation that has already displayed remarkable potential for producing novel, non-pharmacological interventions for depression and cigarette smokers. In this study, investigators will use brain MRI to guide TMS therapy for smoking cessation.",[90,27],[237],"Tobacco use disorder, rTMS, smoking cessation","2026-04-13",{"date":215,"type":33},{"date":241,"type":33},"2021-05-15",{"date":243,"type":21},"2027-04-04",{"name":39,"class":40},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":41},"100544746","noncombustible-nicotine-delivery-systems-as-potential-harm-reduction-tools-for-persistent-cigarette-smokers-100544746","NCT06372899","Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e. speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.\n4. Have a carbon monoxide (CO) greater than 10 ppm.\n5. Not using any forms of nicotine regularly other than cigarettes\n6. Be willing to switch to e-cigarettes or nicotine pouches for 6 weeks.\n7. Plan to live in the area for the duration of the study.\n8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette and nicotine pouch use is defined as greater than 5 days\u002Fpast 30 days.\n\n   a. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.\n2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.\n3. Current use of smoking cessation medication\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n4. Breath alcohol reading (BrAC) greater than .000 at Intake.\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator. Subjects may be deemed ineligible at any point throughout the study.",{"count":253,"type":21},200,[24],"This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value of ECIGS and ONPS relative to combustible cigarettes will be assessed as mechanisms.",[257,27,258,90],"E-cigarette Use","Harm Reduction","2026-03-11",{"date":261,"type":33},"2026-03-12",{"date":263,"type":33},"2024-10-02",{"date":265,"type":21},"2028-03-31",{"name":105,"class":40},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":151},"100494775","phase-2-e-cigarettes-for-harm-reduction-in-smokers-with-opioid-use-disorder-100494775","NCT05722561","E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder","Effectiveness and Impact of Counseling Enhanced With Electronic Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder","Inclusion Criteria:\n\n1. Currently smokes 5 or more CPD\n2. Age ≥ 21 years\n3. Has a diagnosis of Opioid Use Disorder\n4. In OUDTP (buprenorphine or methadone) ≥ 12 weeks via self-report or EHR records\n5. Stable methadone or buprenorphine dose for two weeks via self-report or EHR records\n6. Interested in reducing combustible cigarette (CC) smoking but not necessarily trying to quit\n7. Own a mobile phone or have regular access to a mobile phone.\n8. Able to provide an additional contact to improve follow-up rates.\n\nExclusion Criteria:\n\n1. Does not speak English or Spanish\n2. Are pregnant or breastfeeding\n3. Not able to provide consent\n4. Used tobacco products other than CC in the past 2 weeks (e.g., EC, cigarillo)\n5. Currently engaged in an attempt to quit CC smoking\n6. Reports having severe chronic obstructive pulmonary disease or asthma (i.e., with exacerbation requiring hospitalization or intubation in the prior 6 months)\n7. Reports current major depressive or manic episode, current psychotic disorder, past-year suicide attempt or psychiatric hospitalization, or current suicidal ideation with plan or intent.","75 Years",{"count":276,"type":21},302,[278],"PHASE2","The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes\u002Fe-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking reduction among persons with opioid use disorder (OUD) in methadone and buprenorphine treatment programs (opioid use disorder treatment programs (OUDTP)). OUDTP patients are a population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving meaningful clinical outcomes in tobacco treatment. If effective, electronic cigarettes would provide an additional tool for tobacco harm reduction among this difficult-to-treat vulnerable population.",[281,27],"Opioid Use Disorder",[283,284,285,286,287,288,289],"cigarettes","smoking","smoking reduction","OUD","OUDTP","Buprenorphine","Methadone","2026-03-09",{"date":259,"type":33},{"date":293,"type":33},"2024-08-08",{"date":295,"type":21},"2027-03-01",{"name":297,"class":40},"NYU Langone Health",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":41},"100525189","a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-100525189","NCT06118502","A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse","ADAPT","Inclusion Criteria:\n\n* Smokers who want to quit\n\nExclusion Criteria:\n\n* Non-smokers",{"count":306,"type":21},544,[24],"This is a research study to find out if treatment decision making can be improved for smokers who find it difficult to quit with medications. Everyone who participates in this study will receive free product, either nicotine replacement therapies (patches and lozenges), varenicline, or a harm reduction product (e-cigarette) for a full 12 weeks. Most participants will receive some combination of these treatments, depending on individual response to each.\n\nAll visits and study assessments will be entirely remote. All treatments will be provided free of charge for the first 12 weeks. After that, the study team will contact the participants 6 months after the first study phone call to complete another survey. The study lasts six months and will involve 8 surveys.",[27,28,310],"Treatment","2026-03-04",{"date":313,"type":33},"2026-03-06",{"date":315,"type":33},"2024-03-25",{"date":265,"type":21},{"name":39,"class":40},{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":41},"100536386","the-role-of-flavor-in-the-substitutability-of-e-cigarettes-for-combustible-cigarettes-among-persistent-smokers-100536386","NCT06264154","The Role of Flavor in the Substitutability of E-cigarettes for Combustible Cigarettes Among Persistent Smokers","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e. speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 12 months\n3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.\n4. Ever use of an e-cigarette\n5. Have a carbon monoxide (CO) greater than 10 ppm\n6. Not using any forms of nicotine regularly other than cigarettes\n7. Be willing to switch to e-cigarettes for 6 weeks and use the assigned flavors\n8. Plan to live in the area for the duration of the study\n9. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\nSmoking Behavior Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette use is defined as greater than 5 days\u002Fpast 30 days\n\n1. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.\n2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.\n3. Current use of smoking cessation medication\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n4. Breath alcohol reading (BrAC) greater than .000 at Intake.\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.\n3. Allergies to either propylene glycol or flavor additives\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",{"count":325,"type":21},210,[24],"This between-subjects study aims to evaluate the effect of flavor on initial and sustained switching from combustible cigarettes to e-cigarettes among 210 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to a six-week regimen of fruit-flavored, tobacco-flavored, or menthol-flavored e-cigarettes and be instructed to switch (versus smoking cigarettes) over a 6-week period. Flavor-associated subjective reward and the reinforcing value of flavored e-cigarettes relative to combustible cigarettes will be assessed as mechanisms.",[329,90,27,330],"Smoking","E-Cig Use","2026-02-17",{"date":333,"type":33},"2026-02-19",{"date":335,"type":33},"2024-08-26",{"date":337,"type":21},"2027-12",{"name":105,"class":40},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":16,"sex":17,"minAge":113,"maxAge":274,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":151},"100529438","phase-2-semaglutide-for-post-smoking-cessation-weight-management-100529438","NCT06173778","Semaglutide for Post-Smoking Cessation Weight Management","A Randomized Controlled Trial of Once-Weekly Semaglutide for Limiting Post-Smoking Cessation Weight Gain in Adult Smokers With Overweight\u002FObesity","Inclusion Criteria:\n\n* Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study.\n* Body mass index (BMI) ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical exclusion criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea\n* Have been smoking ≥5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test.\n* Desire to quit smoking (defined as \"intend to quit within one month\")\n* Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).\n* Women of child-bearing potential must provide negative urine pregnancy tests prior to randomization.\n* Normal cognitive restraint (assessed as cognitive restraint score of \\\u003C4 from the Three Factor Eating Habits Questionnaire)\n* Have a medical history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator\n\nExclusion Criteria:\n\nMedical Exclusions\n\n* Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).\n* Acute pancreatitis within the past 6 months prior to screening.\n* History or presence of chronic pancreatitis.\n* Type 1 or type 2 Diabetes Mellitus (previously diagnosed or indicated by HbA1C ≥48 mmol\u002Fmol (6.5%) as measured by central laboratory at screening).\n* End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR \\\u003C 15 ml\u002Fmin\u002F1.73 m2 as measured by central laboratory at screening).\n* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 60 days prior to screening.\n* Systolic blood pressure (SBP) \\>159 mmHg and\u002For diastolic blood pressure (DBP) \\>99 mmHg)\n* History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n* Severe gastrointestinal disease (i.e., severe gastroparesis).\n* Known or suspected hypersensitivity to nicotine\u002Fnicotine patches; semaglutide, excipients, or related products.\n* Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception.\n* Have any illness or condition which in the opinion of the Principal Investigator and\u002For the Study Physician would preclude safe and\u002For successful completion of the study.\n\nPsychiatric \u002F Substance Use Exclusions\n\n* Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 3 months prior to screening (existing diagnosis or as determined by the structured interview).\n* Urine drug test positive, before randomization, for any of the following substances:\n\n  1. benzodiazepines\n  2. cocaine\n  3. opioids\n  4. amphetamines\n  5. methamphetamine\n  6. buprenorphine\n  7. barbiturates\n  8. 3,4-methylenedioxy-methamphetamine (MDMA)\n  9. Tetrahydrocannabinol (THC)\n* Psychotic or bipolar disorder, or mood disorder with psychotic features; or eating disorder (existing clinical diagnosis or as determined by the structured interview)\n* Moderate to high risk for suicidality (as determined by the structured interview).\n\nWeight-Related Exclusions\n\n* Previously undergone bariatric surgery\n* Gained\u002Flost ≥4.5 kg over the past 6 months (prior to screening)\n* Currently enrolled in a behavioral weight management plan\n* Uncontrolled thyroid disease (the criterion will be assessed at the Study Physician's and the Principal Investigator's discretion)\n\nSmoking-Related Exclusions\n\n-Currently using other combustible (e.g., cigars), other (e.g., chewing tobacco, snuff, snus) or alternative (e.g., electronic cigarettes) tobacco products\n\nMedication-Related Exclusions\n\n* Currently using oral or injectable glucose lowering medications\n* Currently using pharmacotherapy for smoking cessation (NRT, varenicline, or bupropion)\n* Currently or recently (last 90 days prior to screening) taking medication used for weight management (i.e., orlistat, lorcaserin,vi naltrexone-bupropion, liraglutide, phentermine, topiramate, benzphetamine, diethylpropion, phendimetrazine)\n* Currently or recently (within the past 14 days prior to screening) taking medication(s) known to impact appetite and\u002For weight (i.e., corticosteroids, excluding inhaled)\n\nGeneral Exclusions\n\n* Current, anticipated, or pending enrollment in another research study during this trial that could potentially affect participant safety and\u002For the study data\u002Fdesign as determined by the Principal Investigator and\u002For Study Physician.\n* Not planning to live in the area for the duration of this trial.\n* Surgery scheduled for the duration of the trial, except for minor surgical procedures, in opinion of the Principal Investigator and\u002For the Study Physician.\n* Unable to communicate (read, write, and speak) fluently in English.",{"count":347,"type":21},197,[278],"This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.",[351,352,27],"Obesity","Overweight",[284,354,283,355,356,357,358,359],"quit smoking","tobacco","overweight","obesity","obesity medications","semaglutide","2026-02-06",{"date":362,"type":33},"2026-02-11",{"date":364,"type":33},"2024-04-23",{"date":366,"type":21},"2026-08-01",{"name":368,"class":40},"The University of Texas Health Science Center, Houston",{"id":370,"slug":4,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":41},"100538816","NCT06295757","Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures","Inclusion Criteria:\n\n* Smoking at least 10 cigarettes\u002Fday for at least 1 year (confirmed by CO \\> 8 ppm or NicAlert test of 6)\n* Engaging in relighting for at least half of their CPD\n* No smoking quit attempts in the past month nor intentions to quit in the next month\n* Stable medical or psychiatric conditions with systolic blood pressure \\\u003C 160, diastolic blood pressure \\\u003C 100 and heart rate \\\u003C 105 bpm\n\nExclusion Criteria:\n\n* Participant with current or recent alcohol or drug abuse problems, use of substances of abuse (other than marijuana due to high prevalence of co-use) within the past month\n* Currently trying or planning to quit smoking in the next month\n* Planning to become pregnant, pregnant or breastfeeding. Pregnancy exclusion will be confirmed through a urine test.",{"count":375,"type":21},30,[24],"Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes.",[90,27,165],"2026-02-02",{"date":381,"type":33},"2026-02-04",{"date":383,"type":33},"2024-10-12",{"date":385,"type":21},"2028-01-01",{"name":387,"class":40},"Masonic Cancer Center, University of Minnesota",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":41},"100562893","phase-1-effect-of-cannabis-on-cigarette-use-behavior-100562893","NCT06609083","Effect of Cannabis on Cigarette Use Behavior","Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Cigarette Use","Inclusion Criteria:\n\n1. Healthy non-treatment seeking adults aged 21 or older\n2. Report daily use of combustible tobacco cigarettes\n3. Biological confirmation of cigarette use: have an expired carbon monoxide (CO) level of more than 5 ppm and a positive urine cotinine test at screening\n4. Report current use of cannabis (at least 1 occasion per week)\n5. Have experience with the inhalation route of administration for cannabis\n6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study.\n\nExclusion Criteria:\n\n1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days\n2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine\n3. Test positive for illicit drugs other than cannabis and tobacco\n4. Positive breath alcohol test at study admission\n5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity\n6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding\n8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)\n9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":396,"type":21},100,[398],"PHASE1","The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of cigarettes. The study's goals are to test demand for cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke cigarettes and either smoke or vape THC in the laboratory.",[401,90,27],"Cannabis Use",[403,404,405,406,355],"cannabis","cigarette","marijuana","THC","2026-01-15",{"date":409,"type":33},"2026-01-16",{"date":411,"type":33},"2025-01-22",{"date":413,"type":21},"2029-10-01",{"name":415,"class":40},"Johns Hopkins University",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":41},"100605325","effects-of-a-low-nicotine-standard-and-tobacco-prices-on-illegal-cigarette-purchasing-100605325","NCT07161050","Effects of a Low Nicotine Standard and Tobacco Prices on Illegal Cigarette Purchasing","Inclusion Criteria:\n\n* Provide informed consent Be at least 21 years of age or older Provide a breath sample for measuring carbon monoxide (CO ≥ 8 ppm) Stable tobacco use patterns for at least two months\n\nExclusion Criteria:\n\nFor exclusive cigarette smokers:\n\nSmoke at least 10 cigarettes daily and do not use NVPs regularly (no more than 9 times in the last month).\n\nFor dual cigarette\u002FNVP users:\n\nSmoke at least 10 cigarettes daily and use NVPs at least 3 times in a week (report use of closed nicotine salt system)\n\nFor both groups:\n\nHave plans to move out of the area Have a serious or unstable physical or mental health condition Taking a tobacco cessation medication or medication that interferes with nicotine metabolism, motivation or reinforcement Report concrete, immediate plans to alter\u002Fquit using their usual nicotine products at the beginning of the study Being pregnant or lactating",{"count":423,"type":21},70,[24],"This study will investigate the effects of a very-low-nicotine cigarette (VLNC) standard, e-cigarette price, and illegal cigarette price on illegal product purchasing and alternative product use in a virtual marketplace.",[27,257],[141,428],"Illegal cigarette","2026-01-14",{"date":409,"type":33},{"date":432,"type":33},"2025-12-01",{"date":434,"type":21},"2026-10-07",{"name":150,"class":40},{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":41},"100568251","evaluation-of-low-and-high-nicotine-tobacco-free-nicotine-pouches-100568251","NCT06678789","Evaluation of Low and High Nicotine Tobacco Free Nicotine Pouches","Evaluation of Low and High Nicotine Tobacco Free Nicotine Pouches as a Harm Reducing Substitute for Combustible Cigarettes - (Pack2Pouch)","Pack2Pouch","Inclusion Criteria:\n\n* Age 21+\n* current cigarette smoking (25+ days per previous month, 5 or more cigarettes\u002Fday, for greater than 1yr, greater than 100 lifetime cigarettes)\n* have not used TNFPs more than 5 times during their lifetime\n* willing and able to attend 2 in-person visits in Charleston (to assess biomarkers)\n* have internet access\n\nExclusion Criteria:\n\n* Lack of proficiency in English.\n* Use of other combustible tobacco products (i.e., cigars, cigarillos, hookahs) and\u002For other non-combusted nicotine\u002Ftobacco products (i.e., e-cigarettes, smokeless tobacco) in the past 30 days.\n* Current use of smoking cessation medications (i.e., varenicline, bupropion, nicotine replacement therapy).\n* Use of marijuana within the past month, and unwillingness to abstain from marijuana during course of study.\n* Medical conditions contraindicated to NRT use (including pregnancy, breastfeeding, and nursing, past month myocardial infarction, current untreated cardiac arrhythmia, current severe angina, current uncontrolled severe vascular disease).",{"count":445,"type":21},50,[24],"Tobacco-free oral nicotine pouches (such as Zyn brand) are a less harmful alternative to cigarette smoking. Pouches, however, contain nicotine, and addictive substance that is not risk-free. The present study is evaluating how well nicotine pouches, at different nicotine levels, help people switch away from smoking cigarettes. People who smoke cigarettes will be asked to answer questions about their tobacco product use and provide breath samples and cheek swab samples at an in-person visit to MUSC Charleston. Participants will then be provided with a 28-day supply of nicotine pouches, and will be asked to switch from smoking to pouches over the course of 4 weeks. Finally, participants will complete a final visit at MUSC, and will answer more questions about their tobacco use 1-month later.",[27,165,449],"Smoking Cessation",[329],"2025-12-17",{"date":453,"type":33},"2025-12-18",{"date":455,"type":33},"2025-02-14",{"date":457,"type":21},"2027-02-28",{"name":39,"class":40},{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":41},"100501895","e-cigarettes-for-harm-reduction-among-smokers-with-serious-mental-illness-100501895","NCT05815199","E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness","Effectiveness and Impact of Counseling Enhanced Using Electronic Cigarettes for Harm Reduction in People With Serious Mental Illness","Inclusion Criteria:\n\n* Currently smokes 5 or more CPD\n* Willingness and ability to provide informed consent\n* Age of at least 21 years\n* Has SMI diagnosis (such as Schizophrenia, Schizoaffective disorders, Bipolar disorder, Depressive disorders, Trauma and stressor related disorders etc.) as determined using the MINI tool\n* Interested in reducing CC smoking but not necessarily trying to quit\n* Own a mobile phone or have regular access to a mobile phone\n* Able to provide an additional contact to improve follow-up rates\n\nExclusion Criteria:\n\n* Is pregnant or breastfeeding\n* Used tobacco other than CC in the past 2 weeks (e.g., EC, cigarillo)\n* Currently engaged in an attempt to quit CC\n* Change in dose of their psychotropic medication(s) in the last 30 days\n* Meeting DSM-V criteria for current alcohol or substance use disorder except for nicotine use disorder and active mild alcohol or substance use disorders.\n* Past month suicidal ideation\u002Fsuicide attempt and\u002For psychiatric hospitalization in the last 30 days",{"count":467,"type":21},60,[24],"In this open-label, randomized controlled trial study, participants who smoke combustible cigarettes (CC) and are diagnosed with Serious Mental Illness (SMI) will be randomized in two arms to receive harm-reduction counseling and Ecological Momentary Intervention text messaging (EMI) along with either e-cigarettes (EC) or nicotine replacement therapy (NRT) such as patch and lozenges to compare the efficacy in CC smoking reduction.",[27],[472,473,62,474],"E-cigarettes","Harm reduction","Serious mental illness","2025-10-08",{"date":477,"type":33},"2025-10-10",{"date":479,"type":33},"2023-11-13",{"date":481,"type":21},"2026-03",{"name":297,"class":40},{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":151},"100457179","phase-2-mobile-health-technology-for-personalized-tobacco-cessation-support-in-laos-100457179","NCT05233228","Mobile Health Technology for Personalized Tobacco Cessation Support in Laos","SupportLaos","Inclusion Criteria: (pilot RCT in the R21 Phase and main RCT in the R33 Phase):\n\n1. aged ≥18 years\n2. self-reported current combustible cigarette smokers (smoked at least 100 cigarettes in lifetime and currently smoke ≥1 cigarette\u002Fday)\n3. willing to set a quit date within 2 weeks of study enrollment\n4. able to provide written informed consent to participate\n5. able to read Lao (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form).\n\nExclusion Criteria: (pilot RCT in the R21 Phase and main RCT in the R33 Phase)\n\n1. history of a medical condition that precludes use of NRT\n2. ineligibility to participate based on medical or psychiatric conditions diagnosed by a physician\u002Fclinician\n3. enrollment in another cessation program or current use of other cessation medications.","65 Years",{"count":492,"type":21},500,[278],"In Lao People's Democratic Republic (Lao PDR), 51% of adult men and 7% of adult women smoke tobacco. The development and evaluation of sustainable tobacco cessation interventions suitable for widespread adoption in nations such as Lao PDR are pressing public health needs. To address this need, the investigators propose a project that adapts a theoretically and empirically based mobile health (mHealth) technology to help people quit smoking cigarettes in Lao PDR. This mHealth approach includes a fully automated, interactive, personalized, smartphone-delivered intervention for behavioral treatment, delivered through our Insight™ platform.\n\nThis proposed project for Lao PDR includes 2 main phases. In the R21 Phase, the investigators will use formative research methods to adapt our intervention content to the sociocultural context, language, and communication styles of Laotians. In the subsequent R33 Phase, the investigators will conduct a randomized controlled trial (RCT) to evaluate the efficacy of our mHealth intervention and technology. Adult smokers of both sexes will be recruited through 2 large hospitals: Setthathirath Hospital in Vientiane and Champasak Hospital in Champasak Province. Participants (n=500) will be randomized to 1 of 2 treatment groups: Standard Care (SC; n=250) or Automated Treatment (AT; n=250). SC consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of NRT (transdermal patches). AT consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos. The primary health outcome of the trial is biochemically confirmed self-reported 7-day point prevalence abstinence 12 months post study enrollment. The project also aims to advance mHealth research capacity in Lao PDR and sustain the US-Lao PDR research network. The project has the potential to transform healthcare services for tobacco cessation treatment throughout the country and, ultimately, to reduce tobacco-induced morbidity and mortality significantly.",[27],"2025-08-11",{"date":498,"type":33},"2025-08-15",{"date":500,"type":33},"2022-04-27",{"date":502,"type":21},"2026-08-31",{"name":174,"class":40},{"id":505,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":25,"conditions":508,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":514,"locationsCount":41},"100544806",{"count":20,"type":21},[24],[27,28],"2025-07-22",{"date":511,"type":33},"2025-07-25",{"date":35,"type":33},{"date":37,"type":21},{"name":39,"class":40},{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":523,"minAge":113,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":41},"100594029","smoking-cessation-for-fathers-of-sick-children-100594029","NCT07014124","Smoking Cessation for Fathers of Sick Children","mHealth-based Motivational Counselling Integrate With a Sample of Nicotine Replacement Therapy for Fathers of Sick Children Who Smoke Cigarettes: A Pilot Randomized Controlled Trial","Quit-for-Love","Inclusion criteria for parents：\n\n* Parents (mainly fathers) aged ≥18 years and smoke at least one cigarette (including alternative tobacco products) daily in the past seven days\n* Living with a child aged \\\u003C18 years who attended the clinic or were admitted to the pediatric ward\n* Hong Kong residents able to read and communicate in Cantonese or Putonghua\n* Owned a smartphone and can use an instant messaging app (e.g., WhatsApp, Facebook) Inclusion criteria for children\n* Children aged \\\u003C18 years who attended the clinic or were admitted to the pediatric ward\n* Lives with at least one or more parents who smoke at least one cigarette (including alternative tobacco products) daily in the past seven days\n* Able to provide biochemical samples (e.g. saliva) for purpose of research\n\nExclusion criteria for parents\n\n* Smokers having a history of psychiatric\u002Fpsychological disease or currently on regular psychotropic medications\n* Smokers using smoking cessation medications or other smoking cessation services or projects Exclusion criteria for children\n* Children who already have serious health diseases (e.g.chronic disease, genetic disease)\n* Children who are participating in other clinical trials that may affect the results of this study\n* Children who live in certain environments, such as those living in highly contaminated areas or areas with other potential disease-causing factors","MALE",{"count":525,"type":21},160,[24],"The project aims to develop and examine the feasibility, acceptability, and preliminary effectiveness of a proactive intervention model combined brief advice, nicotine replacement therapy sampling and mHealth-based individual counselling in increasing smoking abstinence for fathers of sick children.",[27,529],"mHealth Intervention",[531,532,354,64,533,534],"tobacco exposure","sick children","mHealth support","smoking fathers","2025-06-02",{"date":537,"type":33},"2025-06-10",{"date":539,"type":33},"2025-03-18",{"date":541,"type":21},"2026-04-01",{"name":543,"class":40},"The University of Hong Kong",{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":551,"minAge":113,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":22,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":561,"leadSponsor":563,"locationsCount":41},"100543584","smoking-cessation-intervention-for-american-indian-women-experiencing-intimate-partner-violence-100543584","NCT06357767","Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence","Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence","Inclusion Criteria:\n\n* American Indian woman from the Northern Plains\n* Live in Rapid City, SD or surrounding area\n* Willing to quit smoking during study participation\n* 18 years of age or older\n* Smoking at least five cigarettes per day\n* Experienced physical and\u002For psychological IPV in the past three months\n\nExclusion Criteria:\n\n* Inability to give consent and\u002For adequately complete questionnaires due to cognitive impairment.\n* Self-reported pregnancy or intention to become pregnant during the intervention period","FEMALE",{"count":553,"type":21},48,[24],"The goal of this project is to refine and test a culturally-tailored smoking cessation intervention for American Indian women who have experienced intimate partner violence (IPV). The primary aims of this study are to: (a) use a community-based participatory approach to refine intervention materials and finalize pilot intervention methodology for a culturally tailored, trauma-informed smoking cessation intervention for AI women who have experienced IPV; (b) examine feasibility, acceptability, satisfaction, and preliminary efficacy of the intervention; and (c) explore changes in alcohol and drug use over the course of the intervention.\n\nParticipants will be asked to participate in the 8-week Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence, and complete interviews at baseline, end-of-treatment, and three months from the end of treatment.",[449,27],"2024-08-09",{"date":559,"type":33},"2024-08-12",{"date":293,"type":33},{"date":562,"type":21},"2026-01-31",{"name":564,"class":40},"Black Hills Center for American Indian Health",{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":574,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":41},"100397003","the-positively-quit-trial-for-smoking-cessation-100397003","NCT04449458","The Positively Quit Trial for Smoking Cessation","The Positively Quit Trial: Addressing Disproportionate Smoking Rates Among People Living With HIV","Inclusion Criteria:\n\n* greater than or equal to age 18 (as NRT is not FDA approved for adolescents)\n* self-report smoking cigarettes\n* positive cotinine test\n* motivated to quit\n* own a smart phone, laptop, desktop, or tablet computer\n* able to join group from a private space with Internet access\n* demonstrate the ability to connect to the HIPAA-compliant videoconferencing system, Zoom, over the internet h) speak English i) living in the US j) living with certain health conditions\n\nExclusion Criteria:\n\n* pregnant, breastfeeding, or have other contraindications to NRT\n* receiving other tobacco treatment, or\n* inability to communicate coherently in English during the video-conferencing test or other pre-enrollment interactions",{"count":573,"type":21},482,[24],"The main goal of the present study is to determine if a smoking cessation program designed for people living with certain chronic conditions and delivered via videoconferencing groups works better than a control condition--a program that is not designed to help with smoking but that does have the same number of group contact hours as the other program (this program is called the Attention Matched Control condition; AMC) for helping people with certain health conditions stop smoking. People in both groups will receive brief advice to quit and an offer of nicotine replacement therapy patches (NRT), as well as 12 videoconferencing group sessions. The team will measure smoking behavior over a one-year period and compare smoking rates for the treatment condition against AMC to see if the treatment condition is better at getting people living with certain health conditions to quit smoking.",[27],"2024-07-19",{"date":579,"type":33},"2024-07-23",{"date":581,"type":33},"2020-06-10",{"date":583,"type":21},"2026-07-31",{"name":585,"class":40},"University of South Florida"]